Israel China Biotechnology (ICB) Ltd (ICB) - Total Assets
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) holds total assets worth ILA6.66 Million ILA (≈ $17.86K USD) as of June 2021. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ICB net assets for net asset value and shareholders' equity analysis.
Israel China Biotechnology (ICB) Ltd - Total Assets Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's total assets have evolved over time, based on quarterly financial data.
Israel China Biotechnology (ICB) Ltd - Asset Composition Analysis
Current Asset Composition (December 2020)
Israel China Biotechnology (ICB) Ltd's total assets of ILA6.66 Million consist of 25.5% current assets and 74.5% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 24.8% |
| Accounts Receivable | ILA47.00K | 0.6% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA2.01 Million | 24.1% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Israel China Biotechnology (ICB) Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Israel China Biotechnology (ICB) Ltd's current assets represent 25.5% of total assets in 2020, a decrease from 92.2% in 2015.
- Cash Position: Cash and equivalents constituted 24.8% of total assets in 2020, down from 90.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 24.1% of total assets.
Israel China Biotechnology (ICB) Ltd Competitors by Total Assets
Key competitors of Israel China Biotechnology (ICB) Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Meitav Dash Investments Ltd
TA:MTDS
|
Israel | ILA4.45 Billion |
|
Onix Capital Tbk
JK:OCAP
|
Indonesia | Rp9.43 Billion |
|
Poalim Ibi
TA:PIU
|
Israel | ILA171.11 Million |
|
Inbar Group Finance Ltd
TA:INBR
|
Israel | ILA68.55 Million |
|
Aju IB Investment Co. Ltd
KQ:027360
|
Korea | ₩336.45 Billion |
|
Mirae Asset Venture Investment Co. Ltd
KQ:100790
|
Korea | ₩1.08 Trillion |
|
EBEST Investment & Securities Co. Ltd
KQ:078020
|
Korea | ₩10.39 Trillion |
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
Korea | ₩145.68 Billion |
Israel China Biotechnology (ICB) Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.65 | 4.80 |
| Quick Ratio | 0.29 | 0.61 | 4.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-2.27 Million | ILA-1.21 Million | ILA4.58 Million |
Israel China Biotechnology (ICB) Ltd - Advanced Valuation Insights
This section examines the relationship between Israel China Biotechnology (ICB) Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.89 |
| Latest Market Cap to Assets Ratio | 2.33 |
| Asset Growth Rate (YoY) | -27.9% |
| Total Assets | ILA8.34 Million |
| Market Capitalization | $19.47 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Israel China Biotechnology (ICB) Ltd's assets at a significant premium (2.33x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Israel China Biotechnology (ICB) Ltd's assets decreased by 27.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual total assets of Israel China Biotechnology (ICB) Ltd from 2015 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | ILA8.34 Million ≈ $22.37K |
-27.87% |
| 2019-12-31 | ILA11.57 Million ≈ $31.01K |
+17.12% |
| 2018-12-31 | ILA9.88 Million ≈ $26.47K |
+736.16% |
| 2017-12-31 | ILA1.18 Million ≈ $3.17K |
-70.89% |
| 2016-12-31 | ILA4.06 Million ≈ $10.88K |
-50.38% |
| 2015-12-31 | ILA8.18 Million ≈ $21.92K |
-- |
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.